Today: 22 June 2026
D-Wave shares trade uneven after unveiling 2032 quantum targets
2 June 2026
2 mins read

D-Wave shares trade uneven after unveiling 2032 quantum targets

NEW YORK, June 2, 2026, 13:02 EDT

• D-Wave shares pared gains and traded flat by early afternoon, giving up an earlier intraday pop.
• The company’s June 1 filing showed plans for a gate-model system aiming for 100 logical qubits by 2032.
• Roth Capital, Rosenblatt, and B. Riley issued bullish notes following D-Wave’s Investor Day.

D-Wave Quantum Inc. shares ended Tuesday close to flat. The stock had picked up early, but that move didn’t last as traders took stock of the company’s new gate-model quantum computing roadmap. Much of D-Wave’s future potential looks already priced in.

NYSE-listed shares traded at $29.26, up 8 cents, or 0.3%. The stock hit a session high of $31.24 but trailed the wider U.S. tech market. The Invesco QQQ Trust was up 0.3%, while the SPDR S&P 500 ETF Trust gained 0.1% at last check.

D-Wave wants investors to see it as more than an annealing company. Quantum annealing, the approach D-Wave is known for, is mostly used for optimization problems like scheduling or routing. The gate-model approach, based on quantum operations similar to the logic gates in classical computing, is considered a bigger bet for the industry’s future.

D-Wave laid out new quantum hardware goals in a June 1 Form 8-K, saying it’s aiming for 100 logical qubits able to run more than one million operations by 2032. Logical qubits, which are error-corrected versions built from physical qubits, are designed to boost calculation reliability. D-Wave also gave milestones: 17 physical qubits by 2026, 49 in 2027, 181 in 2028, and 10 logical qubits by 2030.

D-Wave chief Alan Baratz says the company has a “highly differentiated and credible path” to fault-tolerant quantum computing, according to a filing exhibit. Fault tolerance lets a system keep working even as some errors hit—still a major problem for the sector. SEC

Wall Street’s first reaction skewed positive. Roth Capital’s Sujeeva De Silva upped his price target to $40 from $30 and kept a Buy, calling the company’s first Investor Day “very well attended,” TipRanks reported. John McPeake at Rosenblatt repeated his Buy with a $43 target. B. Riley lifted its target as well, going to $40 from $36. TipRanks

Quantum stocks were getting a mixed look from investors. Both IonQ and Rigetti Computing, often tracked alongside other public quantum companies, traded up in early afternoon. IonQ gained 0.9% and Rigetti added 0.7%. The group held firmer ground as D-Wave’s early rally faded.

D-Wave is still looking to commercial orders to drive its story, not just wins in research. The company posted first-quarter bookings of $33.4 million in May, with revenue at $2.9 million and a net loss of $18.4 million. As of March 31, D-Wave had $588.4 million in cash and marketable securities. CEO Baratz said it was a quarter of “strong execution, expanding commercial adoption,” though revenue dropped 81% year over year—the prior first quarter got a big boost from an annealing-system sale. D-Wave Quantum

Federal money is in the mix too. D-Wave said in May it signed a letter of intent for $100 million in proposed CHIPS and Science Act funding. If the deal goes through, the U.S. Commerce Department would get $100 million in common stock. D-Wave said the grant still depends on final documents, a key point for investors tracking dilution and timing.

The risks are clear. The roadmap stretches years ahead, leans on technical milestones that could get delayed, and it’s tied to a company still losing money. D-Wave’s own filing says the June 1 roadmap info falls under Regulation FD and makes forward-looking statements. The release also warned results might end up a lot different than what’s in the plan.

The stock isn’t behaving like a post-earnings trade right now. It’s trading as a check on management’s credibility. What comes next isn’t only about price targets—it’s about whether the company can actually convert bookings to revenue, push customers past pilot projects, and reach its first hardware goals before patience wears thin.

Mateusz Kaczmarek is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, semiconductors and global market developments. A graduate of the Poznań University of Economics and Business, he previously worked in financial analysis before moving into business journalism. His reporting focuses on technology companies, market trends and the forces shaping global investment markets.

Stock Market Today

  • 3 Small-Cap Stocks: Risks and Alternatives
    June 22, 2026, 9:44 AM EDT. Small-cap stocks often experience price mispricings due to limited analyst coverage but face growth challenges from subscale operations. Alamo (NYSE:ALG) has seen a 2.2% annual revenue decline over two years and expects only 4.5% sales growth next year, trading at a 15x forward P/E. Insteel (NYSE:IIIN) grew sales 5.9% annually over five years, with rising capital costs and declining cash flow margins, trading at 16.7x forward P/E. Green Plains (NASDAQ:GPRE), with flat sales over five years and a 5.5% gross margin, faces cash burn concerns. These factors contribute to cautious outlooks despite the potential of small caps, highlighting the need for thorough analysis before investing.

Latest articles

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

22 June 2026
Definium Therapeutics (DFTX) soared 64.2% pre-market to $40.19 after its Phase 3 Emerge trial showed DT120, an LSD-based tablet, achieved an 8.1-point placebo-adjusted benefit in major depressive disorder at week six, surpassing analyst expectations; investors now await results from a second trial and regulatory review, with approval and market access risks still ahead.
CRH Plans $8.5 Billion Acquisition of Arcosa

CRH Plans $8.5 Billion Acquisition of Arcosa

22 June 2026
CRH will acquire Arcosa for $150 per share in cash—a 25% premium to Arcosa’s 60-day average price—in an $8.5 billion deal that expands CRH’s U.S. infrastructure and energy transmission footprint; Arcosa shares jumped 7.4% in premarket trading after the news, with closing expected in Q1 2027 pending shareholder and regulatory approval.
Bluejay Diagnostics Stock Nearly Triples After U.S. Manufacturing Deal — Here’s the FDA Catch
Previous Story

Bluejay Diagnostics Stock Nearly Triples After U.S. Manufacturing Deal — Here’s the FDA Catch

Legend Biotech Stock Jumps on Full Response in Small Trial as Traders React Quickly
Next Story

Legend Biotech Stock Jumps on Full Response in Small Trial as Traders React Quickly

Go toTop